Aptose biosciences inc. (APTO)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Dec'17Dec'16Dec'15
Current assets:
Cash and cash equivalents

59,754

79,842

20,686

26,898

16,581

15,299

-

-

10,631

-

-

Investments

30,229

17,758

9,528

8,477

449

440

-

-

798

-

-

Prepaid expenses

886

1,025

285

722

539

646

-

-

322

-

-

Other current assets

117

141

109

168

95

101

-

-

74

-

-

Total current assets

90,986

98,766

30,608

36,265

17,664

16,486

-

-

11,825

-

-

Non-current assets:
Property and equipment

309

334

361

352

379

384

-

-

142

-

-

Right-of-use assets, beginning of period

1,262

1,376

1,491

1,573

1,680

-

-

-

-

-

-

Total non-current assets

1,571

1,710

1,852

1,925

2,059

384

-

-

142

-

-

Cash and cash equivalents (note 4(a))

-

-

-

-

-

-

15,056

17,944

-

7,940

8,311

Investments (note 4(b))

-

-

-

-

-

-

550

520

-

0

5,957

Prepaid expenses and other assets

-

-

-

-

-

-

459

593

-

493

771

Total current assets

-

-

-

-

-

-

16,065

19,057

-

8,433

15,039

Property and equipment

-

-

-

-

-

-

230

231

-

213

314

Total non-current assets

-

-

-

-

-

-

230

231

-

213

314

Total assets

92,557

100,476

32,460

38,190

19,723

16,870

16,295

19,288

11,967

8,646

15,353

Current liabilities:
Accounts payable

2,017

1,960

1,174

1,240

1,170

1,315

-

-

589

-

-

Accrued liabilities

1,884

3,058

2,221

1,486

1,322

1,474

-

-

1,176

-

-

Current portion of lease liability, operating leases

525

521

513

493

485

-

-

-

-

-

-

Total current liabilities

4,426

5,539

3,908

3,219

2,977

2,789

-

-

1,765

-

-

Non-current liabilities:
Lease liability, operating leases

894

1,011

1,124

1,215

1,322

-

-

-

-

-

-

Total liabilities

5,320

6,550

5,032

4,434

4,299

2,789

-

-

-

-

-

Shareholders’ equity:
Common shares, no par value, unlimited authorized shares, 76,269,806 and 76,108,031 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

366,252

365,490

291,344

291,238

267,250

261,072

-

-

231,923

-

-

Additional paid-in capital

38,724

34,649

34,593

34,178

33,625

32,963

-

-

29,365

-

-

Accumulated other comprehensive loss

-4,298

-4,298

-4,303

-4,298

-4,307

-4,316

-

-

-4,316

-

-

Deficit

-313,441

-301,915

-294,206

-287,362

-281,144

-275,638

-

-

-246,770

-

-

Total shareholders’ equity

87,237

93,926

27,428

33,756

15,424

14,081

-

-

10,202

-

-

Total liabilities and shareholders’ equity

92,557

100,476

32,460

38,190

19,723

16,870

-

-

11,967

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

2,370

2,401

-

1,318

1,702

Total current liabilities

-

-

-

-

-

-

2,370

2,401

-

1,318

1,702

Common shares (note 6)

-

-

-

-

-

-

254,715

253,081

-

218,034

212,308

Stock options (note 7)

-

-

-

-

-

-

9,950

9,065

-

7,306

5,740

Contributed surplus

38,724

34,649

34,593

34,178

33,625

32,963

22,950

22,909

29,365

21,413

21,188

Warrants (note 9(c))

-

-

-

-

-

-

-

-

-

0

85

Accumulated other comprehensive loss

-

-

-

-

-

-

-4,298

-4,298

-

-4,298

-4,783

Deficit

-

-

-

-

-

-

-269,392

-263,870

-

-235,127

-220,887

Total shareholders equity

-

-

-

-

-

-

13,925

16,887

-

7,328

13,651

Total liabilities and shareholders equity

-

-

-

-

-

-

16,295

19,288

-

8,646

15,353